Published in Nephrol Dial Transplant on November 01, 2003
Novel polymorphisms associated with tacrolimus trough concentrations: results from a multicenter kidney transplant consortium. Transplantation (2011) 1.29
Therapeutic drug monitoring of atazanavir: surveillance of pharmacotherapy in the clinic. Br J Clin Pharmacol (2005) 1.28
A randomized pharmacokinetic study of generic tacrolimus versus reference tacrolimus in kidney transplant recipients. Am J Transplant (2012) 1.11
Progressive decline in tacrolimus clearance after renal transplantation is partially explained by decreasing CYP3A4 activity and increasing haematocrit. Br J Clin Pharmacol (2015) 1.06
Evaluation of limited sampling methods for estimation of tacrolimus exposure in adult kidney transplant recipients. Br J Clin Pharmacol (2011) 1.02
The interactions of age, sex, body mass index, genetics, and steroid weight-based doses on tacrolimus dosing requirement after adult kidney transplantation. Eur J Clin Pharmacol (2011) 0.96
Medication use and medical comorbidity in patients with chronic hepatitis C from a US commercial claims database: high utilization of drugs with interaction potential. Eur J Gastroenterol Hepatol (2014) 0.93
The pharmacokinetics and immunosuppressive response of tacrolimus in paediatric renal transplant recipients. Pediatr Nephrol (2006) 0.85
Gut microbiota and tacrolimus dosing in kidney transplantation. PLoS One (2015) 0.84
Clinical and genetic factors affecting tacrolimus trough levels and drug-related outcomes in Korean kidney transplant recipients. Eur J Clin Pharmacol (2011) 0.82
The tacrolimus metabolism rate influences renal function after kidney transplantation. PLoS One (2014) 0.80
Potential for drug interactions involving cytochrome P450 in patients attending palliative day care centres: a multicentre audit. Br J Clin Pharmacol (2005) 0.80
Influence of tacrolimus metabolism rate on BKV infection after kidney transplantation. Sci Rep (2016) 0.79
A higher dose requirement of tacrolimus in active Crohn's disease may be related to a high intestinal P-glycoprotein content. Dig Dis Sci (2005) 0.78
Single Nucleotide Polymorphisms in Pediatric Idiopathic Nephrotic Syndrome. Int J Nephrol (2016) 0.76
Switching Stable Kidney Transplant Recipients to a Generic Tacrolimus Is Feasible and Safe, but It Must Be Monitored. J Transplant (2017) 0.75
Effects of dexamethasone coadministered with oseltamivir on the pharmacokinetics of oseltamivir in healthy volunteers. Drug Des Devel Ther (2017) 0.75
Role of tacrolimus combination therapy with mycophenolate mofetil in the prevention of organ rejection in kidney transplant patients. Int J Nephrol Renovasc Dis (2010) 0.75
Transplantation: Immunosuppression and risk of polyomavirus BK replication. Nat Rev Nephrol (2013) 0.75
Influence of tacrolimus metabolism rate on renal function after solid organ transplantation. World J Transplant (2017) 0.75
The Pharmacogenetics of Tacrolimus in Corticosteroid-Sparse Pediatric and Adult Kidney Transplant Recipients. Drugs R D (2017) 0.75
Factors affecting the long-term response to tacrolimus in renal transplant patients: pharmacokinetic and pharmacogenetic approach. Int J Med Sci (2010) 0.75
Prediction of tacrolimus metabolism and dosage requirements based on CYP3A4 phenotype and CYP3A5(*)3 genotype in Chinese renal transplant recipients. Acta Pharmacol Sin (2016) 0.75
Lack of a significant pharmacokinetic interaction between maraviroc and tacrolimus in allogeneic HSCT recipients. J Antimicrob Chemother (2015) 0.75
A comparison of the pharmacokinetics of tacrolimus and microemulsified cyclosporin in paediatric renal transplant recipients. Eur J Clin Pharmacol (2004) 0.75
Complement-binding anti-HLA antibodies and kidney-allograft survival. N Engl J Med (2013) 6.31
Inhibition of the mTORC pathway in the antiphospholipid syndrome. N Engl J Med (2014) 5.33
Antibody-mediated vascular rejection of kidney allografts: a population-based study. Lancet (2012) 4.85
New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003. Transplantation (2003) 3.79
AKT2 is essential to maintain podocyte viability and function during chronic kidney disease. Nat Med (2013) 3.41
DNA topoisomerase II in therapy-related acute promyelocytic leukemia. N Engl J Med (2005) 3.06
Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome. Nat Genet (2013) 2.91
Analysis of risk factors for myelodysplasias, leukemias and death from infection among patients with congenital neutropenia. Experience of the French Severe Chronic Neutropenia Study Group. Haematologica (2005) 2.66
Mutations in INF2 are a major cause of autosomal dominant focal segmental glomerulosclerosis. J Am Soc Nephrol (2011) 2.63
Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood (2008) 2.55
Henoch-Schönlein Purpura in adults: outcome and prognostic factors. J Am Soc Nephrol (2002) 2.44
Clinical and epidemiological assessment of steroid-resistant nephrotic syndrome associated with the NPHS2 R229Q variant. Kidney Int (2009) 2.40
The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases. Blood (2008) 2.21
Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clin Infect Dis (2003) 2.21
Prevalence and management of anemia in renal transplant recipients: a European survey. Am J Transplant (2003) 2.21
Poor response to thiopurine in inflammatory bowel disease: how to overcome therapeutic resistance? Clin Chem (2013) 2.09
NPHS2 mutation analysis shows genetic heterogeneity of steroid-resistant nephrotic syndrome and low post-transplant recurrence. Kidney Int (2004) 2.08
Benefits associated with antiviral treatment in kidney allograft recipients with chronic hepatitis B virus infection. J Hepatol (2012) 2.03
Factors associated with chronic hepatitis in patients with hepatitis E virus infection who have received solid organ transplants. Gastroenterology (2011) 2.01
Analgesic effect of acetaminophen in humans: first evidence of a central serotonergic mechanism. Clin Pharmacol Ther (2006) 2.01
Genotype-phenotype correlation in primary hyperoxaluria type 1: the p.Gly170Arg AGXT mutation is associated with a better outcome. Kidney Int (2009) 2.01
Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood (2005) 1.95
Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. J Am Soc Nephrol (2003) 1.93
High sirolimus levels may induce focal segmental glomerulosclerosis de novo. Clin J Am Soc Nephrol (2007) 1.90
Kidney transplant in black recipients: are African Europeans different from African Americans? Am J Transplant (2005) 1.88
Intravenous immunoglobulin therapy for pure red cell aplasia related to human parvovirus b19 infection: a retrospective study of 10 patients and review of the literature. Clin Infect Dis (2012) 1.84
Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. Transplantation (2003) 1.83
Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05. J Clin Oncol (2010) 1.74
Identification of a gene expression profile associated with operational tolerance among a selected group of stable kidney transplant patients. Transpl Int (2011) 1.73
Addition of cyclophosphamide to steroids provides no benefit compared with steroids alone in treating adult patients with severe Henoch Schönlein Purpura. Kidney Int (2010) 1.71
Effects of vitamin D supplementation on the calcium-phosphate balance in renal transplant patients. Kidney Int (2008) 1.71
Mutations in the ELA2 gene correlate with more severe expression of neutropenia: a study of 81 patients from the French Neutropenia Register. Blood (2004) 1.70
Multivariate analysis of donor risk factors for graft survival in kidney transplantation. Transplantation (2003) 1.69
One-year Results of the Effects of Rituximab on Acute Antibody-Mediated Rejection in Renal Transplantation: RITUX ERAH, a Multicenter Double-blind Randomized Placebo-controlled Trial. Transplantation (2016) 1.68
Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference. Ther Drug Monit (2009) 1.68
Characteristics and outcome of myelodysplastic syndromes (MDS) with isolated 20q deletion: a report on 62 cases. Leuk Res (2011) 1.61
Very long-term follow-up of living kidney donors. Transpl Int (2012) 1.61
Reverse transcriptase-PCR quantification of mRNA levels from cytochrome (CYP)1, CYP2 and CYP3 families in 22 different human tissues. Pharmacogenet Genomics (2007) 1.59
Candesartan improves blood pressure control and reduces proteinuria in renal transplant recipients: results from SECRET. Nephrol Dial Transplant (2009) 1.58
Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia. J Clin Oncol (2003) 1.57
High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a. Blood (2006) 1.55
Autophagy protects renal tubular cells against cyclosporine toxicity. Autophagy (2008) 1.53
Outcomes of renal transplantation in patients with autosomal dominant polycystic kidney disease: a nationwide longitudinal study. Transpl Int (2011) 1.53
Kidney function following nephrectomy: similitude and discrepancies between kidney cancer and living donation. Urol Oncol (2010) 1.53
Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy. Clin Cancer Res (2004) 1.51
Determination of lowest possible creatinine in living-donor kidney renal transplant recipients based on donor kidney function. Transplantation (2008) 1.50
Glutathione S-transferase P1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy. Clin Cancer Res (2006) 1.49
To biopsy or not to biopsy? Should we screen the histology of stable renal grafts? Transplantation (2007) 1.49
Successful renal retransplantation after post-transplant lymphoproliferative disease. Am J Transplant (2004) 1.48
Histologic recurrence of Henoch-Schonlein Purpura nephropathy after renal transplantation on routine allograft biopsy. Transplantation (2011) 1.47
Epidermal growth factor receptor promotes glomerular injury and renal failure in rapidly progressive crescentic glomerulonephritis. Nat Med (2011) 1.46
Sirolimus therapy may cause cardiac tamponade. Transpl Int (2012) 1.43
Clinical and immunological features of very long-term survivors with a single renal transplant. Transpl Int (2012) 1.42
Cidofovir may be deleterious in BK virus-associated nephropathy. Transplantation (2010) 1.41
Cysteamine therapy delays the progression of nephropathic cystinosis in late adolescents and adults. Kidney Int (2011) 1.39
Corticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil, and daclizumab induction in renal transplantation. Transplantation (2005) 1.39
The V617F JAK 2 mutation is not a frequent event in patients with cerebral venous thrombosis without overt chronic myeloproliferative disorder. Thromb Haemost (2008) 1.38
Transient Epstein-Barr virus reactivation in CD3 monoclonal antibody-treated patients. Blood (2009) 1.37
New insights into postrenal transplant hemolytic uremic syndrome. Nat Rev Nephrol (2010) 1.36
The kidney as a reservoir for HIV-1 after renal transplantation. J Am Soc Nephrol (2013) 1.34
Clinical value of mitochondrial mutations in colorectal cancer. J Clin Oncol (2005) 1.33
Transcriptional repression of microRNA genes by PML-RARA increases expression of key cancer proteins in acute promyelocytic leukemia. Blood (2008) 1.30
Early epithelial phenotypic changes predict graft fibrosis. J Am Soc Nephrol (2008) 1.29
Diagnosis of Fanconi anemia in patients with bone marrow failure. Haematologica (2009) 1.25
Detection of free-circulating tumor-associated DNA in plasma of colorectal cancer patients and its association with prognosis. Int J Cancer (2002) 1.24
Association of kidney function, vitamin D deficiency, and circulating markers of mineral and bone disorders in CKD. Am J Kidney Dis (2011) 1.23
mToR inhibitors-induced proteinuria: mechanisms, significance, and management. Transplant Rev (Orlando) (2008) 1.22
Genome-wide characterization of pancreatic adenocarcinoma patients using next generation sequencing. PLoS One (2012) 1.21
The expanding spectrum of renal diseases associated with antiphospholipid syndrome. Am J Kidney Dis (2003) 1.21
Brief communication: case reports of ribavirin treatment for chronic hepatitis E. Ann Intern Med (2010) 1.17
Adverse events associated with mTOR inhibitors. Expert Opin Drug Saf (2012) 1.17
High dose chemotherapy in light chain or light and heavy chain deposition disease. Kidney Int (2004) 1.15
Factors influencing long-term outcome after kidney transplantation. Transpl Int (2013) 1.14
A retrospective analysis of thalidomide therapy in non-HIV-related Kaposi's sarcoma. Dermatology (2007) 1.13
Prevention of renal vascular and glomerular fibrosis by epidermal growth factor receptor inhibition. FASEB J (2004) 1.13
A three-arm study comparing immediate tacrolimus therapy with antithymocyte globulin induction therapy followed by tacrolimus or cyclosporine A in adult renal transplant recipients. Transplantation (2003) 1.13
In vitro metabolism of chloroquine: identification of CYP2C8, CYP3A4, and CYP2D6 as the main isoforms catalyzing N-desethylchloroquine formation. Drug Metab Dispos (2003) 1.12
Replacement kidney lipomatosis after renal transplantation. Transplantation (2005) 1.12